ALK重排肾细胞癌的研究进展
Research Progress of ALK-Rearranged Renal Cell Carcinoma
DOI: 10.12677/acm.2025.15123466, PDF,   
作者: 王瑞珂：天津中医药大学中医学院，天津；张 晶*：天津中医药大学第一附属医院肿瘤科，天津
关键词: ALK重排肾细胞癌；基因易位；靶向治疗；综述；ALK-Rearranged Renal Cell Carcinoma； Gene Translocation； Targeted Therapy； Review
摘要: ALK重排肾细胞癌(ALK-RCC)是WHO泌尿及男性生殖肿瘤分类最新版中一个独特的分子亚型，虽然罕见，但其对ALK抑制剂的有效反应使其有希望成为精准医疗的又一典范。自2011年至今已明确伴侣基因类型的ALK-RCC病例或标本共计60余例，涉及伴侣基因10余种，肿瘤临床表现多样，病理特征具有明显异质性。本文将从分子特征与致癌机制、临床病理学关联、诊断策略、治疗现状四方面进行综述，旨在帮助我们建立对该病的诊断意识，优化诊断策略，明确研究的方向和方法。
Abstract: ALK-rearranged renal cell carcinoma (ALK-RCC) is a unique molecular subtype in the latest edition of the WHO classification of urological and male genital tumors. Although it is rare, its effective response to ALK inhibitors makes it a promising candidate for precision medicine. Since 2011, over 60 cases or specimens of ALK-RCC with clearly identified fusion genes have been reported, involving more than 10 fusion genes. The clinical manifestations of the tumors are diverse, and the pathological features show significant heterogeneity. Our article will review the disease from four aspects: molecular characteristics and oncogenic mechanisms, clinical pathological correlation, diagnostic strategies, and current treatment status. The aim is to help us establish diagnostic awareness of the disease, optimize diagnostic strategies, and clarify the direction and methods of research.
文章引用：王瑞珂, 张晶. ALK重排肾细胞癌的研究进展[J]. 临床医学进展, 2025, 15(12): 746-756. https://doi.org/10.12677/acm.2025.15123466

参考文献

[1] Moch, H., Amin, M.B., Berney, D.M., Compérat, E.M., Gill, A.J., Hartmann, A., et al. (2022) The 2022 World Health Organization Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. European Urology, 82, 458-468. [Google Scholar] [CrossRef] [PubMed]
[2] Du, Z. and Lovly, C.M. (2018) Mechanisms of Receptor Tyrosine Kinase Activation in Cancer. Molecular Cancer, 17, 58-70. [Google Scholar] [CrossRef] [PubMed]
[3] Debelenko, L.V., Raimondi, S.C., Daw, N., Shivakumar, B.R., Huang, D., Nelson, M., et al. (2011) Renal Cell Carcinoma with Novel VCL-ALK Fusion: New Representative of Alk-Associated Tumor Spectrum. Modern Pathology, 24, 430-442. [Google Scholar] [CrossRef] [PubMed]
[4] Sugawara, E., Togashi, Y., Kuroda, N., Sakata, S., Hatano, S., Asaka, R., et al. (2012) Identification of Anaplastic Lymphoma Kinase Fusions in Renal Cancer: Large-Scale Immunohistochemical Screening by the Intercalated Antibody-Enhanced Polymer Method. Cancer, 118, 4427-4436. [Google Scholar] [CrossRef] [PubMed]
[5] Kusano, H., Togashi, Y., Akiba, J., Moriya, F., Baba, K., Matsuzaki, N., et al. (2016) Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene. American Journal of Surgical Pathology, 40, 761-769. [Google Scholar] [CrossRef] [PubMed]
[6] Cajaiba, M.M., Jennings, L.J., George, D. and Perlman, E.J. (2016) Expanding the Spectrum of ALK‐Rearranged Renal Cell Carcinomas in Children: Identification of a Novel HOOK1‐ALK Fusion Transcript. Genes, Chromosomes and Cancer, 55, 814-817. [Google Scholar] [CrossRef] [PubMed]
[7] Hang, J., Chung, H. and Pan, C. (2020) ALK-Rearranged Renal Cell Carcinoma with a Novel PLEKHA7-ALK Translocation and Metanephric Adenoma-Like Morphology. Virchows Archiv, 476, 921-929. [Google Scholar] [CrossRef] [PubMed]
[8] Kuroda, N., Trpkov, K., Gao, Y., Tretiakova, M., Liu, Y.J., Ulamec, M., et al. (2020) ALK Rearranged Renal Cell Carcinoma (ALK-RCC): A Multi-Institutional Study of Twelve Cases with Identification of Novel Partner Genes CLIP1, KIF5B and Kiaa1217. Modern Pathology, 33, 2564-2579. [Google Scholar] [CrossRef] [PubMed]
[9] Liu, Y., Li, X., Fan, Y., Xu, H., Gu, Y., Dong, L., et al. (2023) Exploration of Clinicopathological Features of Rearranged Renal Cell Carcinoma and TFE3, TFEB, and ALK Staining Performance in Renal Entities. Heliyon, 9, e15159. [Google Scholar] [CrossRef] [PubMed]
[10] Gupta, S., Krishna, M. and Cheville, J.C. (2024) Alk-rearranged Renal Cell Carcinoma with Nuclear Mitotic Apparatus Protein 1 (NUMA1) as a Fusion Partner. Human Pathology, 149, 75-76. [Google Scholar] [CrossRef] [PubMed]
[11] Zhao, M., Yin, X., Yang, X., Gan, H., Chen, N., Duan, G., et al. (2024) Alk-Rearranged Renal Cell Carcinoma: A Multi-Institutional Study of 9 Cases with Expanding the Morphologic and Molecular Genetic Spectrum. Modern Pathology, 37, Article ID: 100536. [Google Scholar] [CrossRef] [PubMed]
[12] Kathuria-Prakash, N., Lopez, L.P., Raman, S., Ye, H., Anaokar, J., Sisk, A., et al. (2024) ALK Inhibition with Alectinib for Refractory Metastatic Renal Cell Carcinoma with ALK Rearrangement: A Rare Case Report and Literature Review. JCO Precision Oncology, 8, e2400154. [Google Scholar] [CrossRef] [PubMed]
[13] Morris, S.W., Kirstein, M.N., Valentine, M.B., Dittmer, K.G., Shapiro, D.N., Saltman, D.L., et al. (1994) Fusion of a Kinase Gene, ALK, to a Nucleolar Protein Gene, NPM, in Non-Hodgkin’s Lymphoma. Science, 263, 1281-1284. [Google Scholar] [CrossRef] [PubMed]
[14] Shreenivas, A., Janku, F., Gouda, M.A., Chen, H., George, B., Kato, S., et al. (2023) ALK Fusions in the Pan-Cancer Setting: Another Tumor-Agnostic Target? npj Precision Oncology, 7, Article No. 101. [Google Scholar] [CrossRef] [PubMed]
[15] Sukov, W.R., Hodge, J.C., Lohse, C.M., Akre, M.K., Leibovich, B.C., Thompson, R.H., et al. (2012) ALK Alterations in Adult Renal Cell Carcinoma: Frequency, Clinicopathologic Features and Outcome in a Large Series of Consecutively Treated Patients. Modern Pathology, 25, 1516-1525. [Google Scholar] [CrossRef] [PubMed]
[16] Lee, C., Park, J.W., Suh, J.H., Nam, K.H. and Moon, K.C. (2013) Alk-Positive Renal Cell Carcinoma in a Large Series of Consecutively Resected Korean Renal Cell Carcinoma Patients. Korean Journal of Pathology, 47, 452-457. [Google Scholar] [CrossRef] [PubMed]
[17] Yu, W., Wang, Y., Jiang, Y., Zhang, W. and Li, Y. (2017) Genetic Analysis and Clinicopathological Features of ALK‐Rearranged Renal Cell Carcinoma in a Large Series of Resected Chinese Renal Cell Carcinoma Patients and Literature Review. Histopathology, 71, 53-62. [Google Scholar] [CrossRef] [PubMed]
[18] Tao, J.J., Wei, G., Patel, R., Fagan, P., Hao, X., Bridge, J.A., et al. (2018) ALK Fusions in Renal Cell Carcinoma: Response to Entrectinib. JCO Precision Oncology, 2, 1-8. [Google Scholar] [CrossRef] [PubMed]
[19] Tekin, B., Hofich, C.D., Pitel, B.A., Schoolmeester, J.K., Whaley, R.D., Raghunathan, A., et al. (2024) Next Generation Sequencing-Based Identification of Fusion-Driven Renal Neoplasia: A Single Institution Experience. Human Pathology, 152, Article ID: 105542. [Google Scholar] [CrossRef] [PubMed]
[20] Doğan, K. and Onder, E. (2024) ALK-Rearranged Renal Cell Carcinoma (ALK-RCC): Evaluation of Histomorphological and Immunohistochemical Features by Analysis of 276 Renal Cell Carcinoma Cases in Turkey. Pathology—Research and Practice, 253, Article ID: 154951. [Google Scholar] [CrossRef] [PubMed]
[21] Gorczynski, A., Czapiewski, P., Korwat, A., Budynko, L., Prelowska, M., Okon, K., et al. (2019) Alk-Rearranged Renal Cell Carcinomas in Polish Population. Pathology—Research and Practice, 215, Article ID: 152669. [Google Scholar] [CrossRef] [PubMed]
[22] Cajaiba, M.M., Jennings, L.J., Rohan, S.M., Perez‐Atayde, A.R., Marino‐Enriquez, A., Fletcher, J.A., et al. (2016) ALK‐Rearranged Renal Cell Carcinomas in Children. Genes, Chromosomes and Cancer, 55, 442-451. [Google Scholar] [CrossRef] [PubMed]
[23] Mariño‐Enríquez, A., Ou, W., Weldon, C.B., Fletcher, J.A. and Pérez‐Atayde, A.R. (2010) ALK Rearrangement in Sickle Cell Trait‐Associated Renal Medullary Carcinoma. Genes, Chromosomes and Cancer, 50, 146-153. [Google Scholar] [CrossRef] [PubMed]
[24] Smith, N.E., Deyrup, A.T., Mariño-Enriquez, A., Fletcher, J.A., Bridge, J.A., Illei, P.B., et al. (2014) VCL-ALK Renal Cell Carcinoma in Children with Sickle-Cell Trait: The Eighth Sickle-Cell Nephropathy. American Journal of Surgical Pathology, 38, 858-863. [Google Scholar] [CrossRef] [PubMed]
[25] Wangsiricharoen, S., Zhong, M., Ranganathan, S., Matoso, A. and Argani, P. (2021) ALK-Rearranged Renal Cell Carcinoma (RCC): A Report of 2 Cases and Review of the Literature Emphasizing the Distinction between VCL-ALK and Non-VCL-ALK RCC. International Journal of Surgical Pathology, 29, 808-814. [Google Scholar] [CrossRef] [PubMed]
[26] Wang, X., Fang, R., Ye, S., Zhang, R., Li, R., Wang, X., et al. (2019) Targeted Next-Generation Sequencing Revealed Distinct Clinicopathologic and Molecular Features of VCL-ALK RCC: A Unique Case from an Older Patient without Clinical Evidence of Sickle Cell Trait. Pathology—Research and Practice, 215, Article ID: 152651. [Google Scholar] [CrossRef] [PubMed]
[27] 狄世豪, 王小桐, 夏秋媛, 等. 间变性淋巴瘤激酶易位性肾细胞癌临床病理分析[J]. 中华病理学杂志, 2022, 51(1): 28-32.
[28] Zhang, X., Ban, C., Chen, Y., Zhang, S. and Chen, H. (2025) ALK-Rearranged Renal Cell Carcinoma: A Study of Three Cases with Clinicopathologic Features and Effect of Postoperative Adjuvant Immunotherapy. Clinical Genitourinary Cancer, 23, Article ID:102266. [Google Scholar] [CrossRef] [PubMed]
[29] Sangoi, A.R., Kimm, S.Y. and Chan, E. (2021) VCL-ALK Renal Cell Carcinoma in Adult Patient without Sickle Cell Trait. Human Pathology: Case Reports, 25, Article ID: 200528. [Google Scholar] [CrossRef] 
[30] Galea, L.A., Hildebrand, M.S., Witkowski, T., Joy, C., McEvoy, C.R., Hanegbi, U., et al. (2022) ALK-Rearranged Renal Cell Carcinoma with TPM3::ALK Gene Fusion and Review of the Literature. Virchows Archiv, 482, 625-633. [Google Scholar] [CrossRef] [PubMed]
[31] Chen, W., Li, W., Bai, B. and Wei, H. (2020) Identification of Anaplastic Lymphoma Kinase Fusions in Clear Cell Renal Cell Carcinoma. Oncology Reports, 43, 817-826. [Google Scholar] [CrossRef] [PubMed]
[32] Kanakaraj, J., Chang, J., Hampton, L.J. and Smith, S.C. (2024) The New WHO Category of “Molecularly Defined Renal Carcinomas”: Clinical and Diagnostic Features and Management Implications. Urologic Oncology: Seminars and Original Investigations, 42, 211-219. [Google Scholar] [CrossRef] [PubMed]
[33] Kuroda, N., Sugawara, E., Kusano, H., Yuba, Y., Yorita, K. and Takeuchi, K. (2018) A Review of Alk-Rearranged Renal Cell Carcinomas with a Focus on Clinical and Pathobiological Aspects. Polish Journal of Pathology, 69, 109-113. [Google Scholar] [CrossRef] [PubMed]
[34] Zhang, X., Bolck, H.A., Rupp, N.J. and Moch, H. (2023) Genomic Alterations and Diagnosis of Renal Cancer. Virchows Archiv, 484, 323-337. [Google Scholar] [CrossRef] [PubMed]
[35] Williamson, S.R., Gill, A.J., Argani, P., Chen, Y., Egevad, L., Kristiansen, G., et al. (2020) Report from the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers: III: Molecular Pathology of Kidney Cancer. American Journal of Surgical Pathology, 44, e47-e65. [Google Scholar] [CrossRef] [PubMed]
[36] Albertson, D., Barry, M., Liu, T., Mahlow, J. and Sirohi, D. (2024) Genotype Phenotype Correlation of Renal Tumors in the Cancer Genome Atlas Database. International Journal of Surgical Pathology, 33, 289-301. [Google Scholar] [CrossRef] [PubMed]
[37] Roskoski, R. (2013) Anaplastic Lymphoma Kinase (ALK): Structure, Oncogenic Activation, and Pharmacological Inhibition. Pharmacological Research, 68, 68-94. [Google Scholar] [CrossRef] [PubMed]
[38] 中国医师协会肿瘤医师分会, 中国医疗保健国际交流促进会肿瘤内科学分会. 间变性淋巴瘤激酶酪氨酸激酶抑制剂治疗非小细胞肺癌指南(2025版) [J]. 中华肿瘤杂志, 2025, 47(4): 283-297.
[39] Melosky, B., Chu, Q.S.C., Juergens, R.A., Snow, S., Blais, N., Cheema, P., et al. (2025) Canadian Perspectives Revisited: Consensus on the Management of ALK-Rearranged NSCLC. Lung Cancer, 208, Article ID: 108717. [Google Scholar] [CrossRef] 
[40] Pal, S.K., Bergerot, P., Dizman, N., Bergerot, C., Adashek, J., Madison, R., et al. (2018) Responses to Alectinib in ALK-Rearranged Papillary Renal Cell Carcinoma. European Urology, 74, 124-128. [Google Scholar] [CrossRef] [PubMed]
[41] Zhou, S., Sun, G., Wang, J. and Zhang, H. (2020) Anaplastic Lymphoma Kinase (ALK) Rearrangement in Adult Renal Cell Carcinoma with Lung Metastasis: A Case Report and Literature Review. Translational Andrology and Urology, 9, 2855-2861. [Google Scholar] [CrossRef] [PubMed]
[42] Varchetta, V., Campanella, C., Rossi, M., et al. (2021) Identification of Anaplastic Lymphoma Kinase Fusion in Clear Cell Renal Carcinoma (ALK-tRCC): A Precision Oncology Medicine Case Report. Recenti Progressi in Medicina, 112, 14e-15e.
[43] 先洁, 尹晓雪, 王铎淏, 等. 伴肺转移的STRN:ALK重排肾细胞癌1例[J]. 中华病理学杂志, 2024, 53(6): 631-633.
[44] Elhassan, E., Girleanu, C., Kelly, P., Power, D.G., Sweeney, P., Mayer, N., et al. (2024) Anaplastic Lymphoma Kinase (ALK)-Rearranged Renal Cell Carcinoma: A Case Report Highlighting Diagnostic Challenges and Therapeutic Opportunities. Cureus, 16, e65621. [Google Scholar] [CrossRef] [PubMed]

为你推荐